{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:05:37Z","timestamp":1774566337605,"version":"3.50.1"},"reference-count":34,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: In triple-negative breast cancer (TNBC), the addition of immunotherapy has significantly improved outcomes. Immune-related adverse events (irAEs) can be accelerated in patients with pre-existing autoimmune (AI) conditions. The treatment-response standardized protocol used in clinical care raises concerns about the need for right-sizing strategies. As the use of immunotherapy expands, recognizing toxicity from recurrence and optimizing response-adapted approaches are essential to balance cure with quality of survival. Case Presentation: A 38-year-old pregnant woman with a distant history of uveitis and psoriasis was discovered to have pregnancy-associated TNBC. Postnatally, she was treated with neoadjuvant chemotherapy and pembrolizumab, followed by wire-guided left breast wide local excision and sentinel lymph node biopsy of the left axilla. After surgery, residual cancer was noted. She continued adjuvant pembrolizumab and adjuvant radiotherapy 40.05 Gy\/15 fr to the breast and nodes, followed by a 13.35 Gy\/5 fr boost to the tumour bed (breast). Despite a persistent residual tumour, pembrolizumab was continued as per protocol in a response-agnostic manner. At the end of one year of adjuvant pembrolizumab, she developed progressive numbness and weakness in the ipsilateral arm, initially raising suspicion for local recurrence. Comprehensive MRI and PET-CT imaging did not identify recurrent tumour or new metastatic disease. Electromyography confirmed a lower-trunk brachial plexopathy without a structural cause. An immune-mediated process was diagnosed by a process of elimination. Despite treatment with 1st-line high-dose corticosteroids and 2nd-line intravenous immunoglobulin (IVIG), improvement was limited. Therapeutic plasmapheresis led to marked functional recovery and symptom resolution 20 months later. Discussion: Four main challenges are identified: (1) the diagnostic difficulty in identifying local recurrence or radiation injury from immune-related neuropathy; (2) the emerging therapeutic role of plasmapheresis in steroid-refractory irAEs; (3) the possible inconsistencies between rare toxicities observed in clinical trials vs. clinical practice; and (4) the limitations in response in adjuvant therapy, particularly in patients with coexisting AI conditions. Conclusions: Early recognition and accurate distinction from tumour recurrence, as well as support for plasmapheresis as a potential option in steroid-refractory presentations, have been shown to improve patient survival and symptom reduction. With increasing use of immunotherapy, real-world toxicity data, predictive biomarkers, and personalized treatment strategies are urgently needed to balance cure with long-term functional outcomes.<\/jats:p>","DOI":"10.3390\/curroncol33020125","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T08:50:03Z","timestamp":1771577403000},"page":"125","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Perplexing Plexopathy After Pembrolizumab Therapy in Early-Stage Triple-Negative Breast Cancer"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5788-0060","authenticated-orcid":false,"given":"Toluwalogo","family":"Baiyewun","sequence":"first","affiliation":[{"name":"University College Cork Cancer Center, Cork University Hospital, T12 DC4A Cork, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"McNamara","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurophysiology, Cork University Hospital, T12 DC4A Cork, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Aherne","sequence":"additional","affiliation":[{"name":"Department of Radiology, Cork University Hospital, T12 DC4A Cork, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex James","family":"Bryan","sequence":"additional","affiliation":[{"name":"University College Cork Cancer Center, Cork University Hospital, T12 DC4A Cork, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Twomey","sequence":"additional","affiliation":[{"name":"University College Cork Cancer Center, Cork University Hospital, T12 DC4A Cork, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sorcha","family":"NiLoingsigh","sequence":"additional","affiliation":[{"name":"Blood Transfusion Service Board, St Finbar\u2019s Hospital, T12 Y319 Cork, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bolanle","family":"Ofi","sequence":"additional","affiliation":[{"name":"University College Cork Cancer Center, Cork University Hospital, T12 DC4A Cork, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek","family":"Power","sequence":"additional","affiliation":[{"name":"University College Cork Cancer Center, Cork University Hospital, T12 DC4A Cork, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2887-7336","authenticated-orcid":false,"given":"Seamus","family":"O\u2019Reilly","sequence":"additional","affiliation":[{"name":"University College Cork Cancer Center, Cork University Hospital, T12 DC4A Cork, Ireland"},{"name":"Cancer Research@UCC, University College Cork, T12 CY82 Cork, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for Early Triple-Negative Breast Cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"104473","DOI":"10.1016\/j.breast.2025.104473","article-title":"Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: Real-world data from the Neo-Real\/GBECAM 0123 study","volume":"83","author":"Andrade","year":"2025","journal-title":"Breast"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/OP.24.00371","article-title":"Real-World Immune-Related Adverse Events in Patients with Early Triple-Negative Breast Cancer Who Received Pembrolizumab","volume":"21","author":"Jayan","year":"2025","journal-title":"JCO Oncol. Pract."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"ltac012","DOI":"10.1093\/immadv\/ltac012","article-title":"Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: An early window of opportunity?","volume":"2","author":"Katsumoto","year":"2022","journal-title":"Immunother. Adv."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2458948","DOI":"10.1080\/21645515.2025.2458948","article-title":"Immune checkpoint inhibitors in cancer patients with autoimmune disease: Safety and efficacy","volume":"21","author":"Le","year":"2025","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41584-022-00841-0","article-title":"Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases","volume":"18","author":"Tison","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Liu, X., Li, S., Ke, L., and Cui, H. (2024). Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: A systematic review and meta-analysis. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12256-z"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Yu, Y., Zhou, Y., Zhang, X., Tan, K., Zheng, J., Li, J., and Cui, H. (2022). Immune Checkpoint Inhibitors in the Treatment of Patients with Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.934093"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e003066","DOI":"10.1136\/jitc-2021-003066","article-title":"Immune checkpoint inhibitors in patients with pre-existing psoriasis: Safety and efficacy","volume":"9","author":"Halle","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.abd.2023.09.003","article-title":"Psoriasis de novo or exacerbation by PD-1 checkpoint inhibitors","volume":"99","author":"Wan","year":"2024","journal-title":"An. Bras. De Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1007\/s00415-023-11625-1","article-title":"Peripheral nervous system adverse events associated with immune checkpoint inhibitors","volume":"270","author":"Rossi","year":"2023","journal-title":"J. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e701","DOI":"10.1016\/j.clbc.2024.08.005","article-title":"Detrimental Impact of Chemotherapy Dose Reduction or Discontinuation in Early Stage Triple-Negative Breast Cancer Treated with Pembrolizumab and Neoadjuvant Chemotherapy: A Multicenter Experience","volume":"24","author":"Krishnan","year":"2024","journal-title":"Clin. Breast Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2275846","DOI":"10.1080\/2162402X.2023.2275846","article-title":"Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancer","volume":"12","author":"Marhold","year":"2023","journal-title":"Oncoimmunology"},{"key":"ref_16","first-page":"943","article-title":"Oncology\u2019s ongoing struggle with evaluating quality of life limiting, treatment-related toxicity","volume":"33","author":"Gaynor","year":"2025","journal-title":"Support. Care Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/jamaoncol.2025.5376","article-title":"Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens","volume":"12","author":"Wildiers","year":"2026","journal-title":"JAMA Oncol."},{"key":"ref_18","first-page":"e60067","article-title":"Magnetic Resonance Imaging of Radiation-Induced Brachial Plexopathy","volume":"16","author":"Shetty","year":"2024","journal-title":"Cureus"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s00701-024-06381-8","article-title":"Brachial plexopathy due to perineural tumor spread: A retrospective single-center experience of clinical manifestations, diagnosis, treatments, and outcomes","volume":"166","author":"Im","year":"2024","journal-title":"Acta Neurochir."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jhsa.2024.09.026","article-title":"Radiation Plexopathy","volume":"50","author":"Mosa","year":"2025","journal-title":"J. Hand Surg. Am."},{"key":"ref_21","first-page":"100764","article-title":"Ultra-hypofractionated one-week locoregional radiotherapy for patients with early breast cancer: Acute toxicity results","volume":"46","author":"Ratosa","year":"2024","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Chomchai, T., Klunklin, P., Tongprasert, S., Kanthawang, T., Toapichattrakul, P., and Chitapanarux, I. (2024). Is there any radiation-induced brachial plexopathy after hypofractionated postmastectomy radiotherapy with helical tomotherapy?. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1392313"},{"key":"ref_23","first-page":"e73043","article-title":"Severe Radiation-Induced Brachial Plexopathy: A Case Report on Radiation Toxicity in a Patient with Invasive Ductal Carcinoma","volume":"16","author":"Waeldner","year":"2024","journal-title":"Cureus"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Brahmer","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/14740338.2020.1738382","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"19","author":"Haugh","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1111\/trf.17114","article-title":"Therapeutic plasma exchange in the management of immune checkpoint inhibitor-associated immune-related adverse effects: A review","volume":"62","author":"Onwuemene","year":"2022","journal-title":"Transfusion"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000528556","article-title":"Therapeutic Plasmapheresis: A Revision of Literature","volume":"48","author":"Altobelli","year":"2023","journal-title":"Kidney Blood Press. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s11481-021-10004-9","article-title":"The Role of Plasma Exchange in the Treatment of Refractory Autoimmune Neurological Diseases: A Narrative Review","volume":"16","author":"Jacob","year":"2021","journal-title":"J. Neuroimmune Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2147\/ITT.S388151","article-title":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Current Therapeutic Approaches and Future Outlooks","volume":"13","author":"Rajabally","year":"2024","journal-title":"ImmunoTargets Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.mayocpiqo.2017.07.004","article-title":"Brachial Plexus Neuritis Associated with Anti-Programmed Cell Death-1 Antibodies: Report of 2 Cases","volume":"1","author":"Alhammad","year":"2017","journal-title":"Mayo Clin. Proc. Innov. Qual. Outcomes"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Shen, X., Yang, J., Qian, G., Sheng, M., Wang, Y., Li, G., and Yan, J. (2024). Treatment-related adverse events of immune checkpoint inhibitors in clinical trials: A systematic review and meta-analysis. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1391724"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1200\/JCO.24.00372","article-title":"Academic Uphill Battle to Personalize Treatment for Patients with Stage II\/III Triple-Negative Breast Cancer","volume":"42","author":"Kok","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e000868","DOI":"10.1136\/bmjonc-2025-000868","article-title":"Incidence of fractures in patients with solid cancers treated with immune checkpoint inhibitors: A systematic review and meta-analysis of randomised controlled trials","volume":"4","author":"Yavropoulou","year":"2025","journal-title":"BMJ Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/s43018-025-00990-7","article-title":"The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types","volume":"6","author":"Awada","year":"2025","journal-title":"Nat. Cancer"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/2\/125\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T09:05:00Z","timestamp":1771578300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/2\/125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["curroncol33020125"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33020125","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]}}}